adhdresearch.news
← Latest research
Paper published Added
PubMed

Brain Waste-Clearance Marker Is Lower Across Psychiatric Disorders

Researchers pooled 24 brain-imaging studies and found that people with psychiatric conditions, including ADHD among several others, scored lower than healthy people on a scan marker linked to how the brain clears waste. The studies varied a lot, and the result isn't broken out for ADHD alone. The marker is an indirect estimate, so it can't show cause.

What you can do

Nothing to change today: treat this as an early research signal about shared brain mechanisms, not something that applies to ADHD specifically or that you can act on.

Evidence
Study design
meta-analysis
Population
Patients with psychiatric disorders versus healthy controls in 32 studies in the systematic review; 24 studies (n = 2855; 1503 patients, 1352 controls) in the meta-analysis. The abstract does not give ADHD-specific numbers or ages.
Sample size
Total: 2855; Exposure / intervention group: 1503; Comparator group: 1352; Meta-analysis of 24 studies reporting bilateral DTI-ALPS; 'intervention' is the patient count and 'comparator' the healthy control count. The systematic review included 32 studies. The number of ADHD studies and participants is not reported in the abstract.
Intervention / exposure
Not reported
Comparator
Healthy controls (patient-control comparisons of DTI-ALPS index)
Key results
  • Bilateral DTI-ALPS index (diffusion tensor imaging along the perivascular space), a non-invasive proxy for glymphatic-related processes: Significant transdiagnostic reduction in DTI-ALPS index in psychiatric populations compared with healthy controls (Hedges' g = -0.78, 95% CI -1.01 to -0.55, p < 0.0001).
  • Between-study heterogeneity: Substantial heterogeneity (I² = 86.3%).
  • Small-study effects: There was evidence of small-study effects.
Effect estimates
  • standardized mean difference: Hedges' g = -0.78 · 95% CI -1.01 to -0.55 · p < 0.0001 · Pooled random-effects comparison of bilateral DTI-ALPS index in psychiatric populations versus healthy controls (24 studies, transdiagnostic, not ADHD-specific)
  • other: I² = 86.3% · Between-study heterogeneity of the pooled DTI-ALPS estimate
Limitations
  • Between-study heterogeneity was substantial (I² = 86.3%).
  • There was evidence of small-study effects, which can inflate pooled estimates.
  • The pooled effect is transdiagnostic; the abstract reports no ADHD-specific effect size, so it cannot be assumed to apply to ADHD alone.
  • DTI-ALPS is an indirect, non-invasive proxy for glymphatic-related processes, not a direct measure of glymphatic function.
  • Authors state that harmonised imaging pipelines and multimodal validation are needed to clarify the biological and clinical significance of the findings.
  • Patient-control comparisons imply cross-sectional data, so the findings cannot establish causation or direction. This is an inference, not an author statement.
  • Abstract-only input: risk-of-bias results and moderator analyses are not reported in the abstract.
Source reviewed
Abstract
References

Pascucci A, Saccaro LF, Forrer S et al. Transdiagnostic reductions in glymphatic-related perivascular diffusion across psychiatric disorders: A systematic review and meta-analysis. Neuroscience and biobehavioral reviews. 2026-10-13